Main > > >COLON CANCER. *

Adjuvant. Dukes C (Stage III). Brand
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil.
USA Approval Date: 1998. 04.30.
(*) Company : Roche>Genentech.
Patent : Expired.
TradeMark: Xeloda.
UpDate: 2018. 09.27.




Adjuvant. Dukes C (Stage III). Generic.
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil.
USA Launch Date: 2019. 04.08.
(*) Company: Armas Pharmaceuticals.
UpDate: 2019. 11.14.




Companion Diagnostics.
"Biopsy>Liquid Biopsy CTCs+ctDNA"
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.12.




Companion Diagnostics. (METASTATIC;
NRAS+).
Liquid Biopsy>Blood Test.
USA Launch Date: 2017. 09.05.
(*) Company: BioCept Inc.
UpDate: 2018. 09.28.




Diagnostics. Balloon Endoscope.
Approved in EU & IL.
USA Approval Date: 2020. 05.26.
Practiced at IL Hospital ..
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 05.27.




Diagnostics. Capsule-Based System.
Preparation-Free.
Utilizing Ultra-Low Dose X-Ray &
Wireless Communication Technologies ..
EU Approval Date: 2018. 01.10.
IL Approval Date: 2018. 09.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.




Diagnostics. Colonoscopy. Cleansing. Na PicoSulfate+MgO+Anhydrous+Citric Acid Ready-to-Drink Low-Volume Premixed Liquid Solution.
USA 2nd Approval : 2017. 11.29.
USA Initial Approval: 2012.
USA Launch Date : 2018. 02.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.




Diagnostics. Colonoscopy. Cleansing. Na2SO4/K2SO4/MgSO4 Oral Solution.
USA Approval Date: 2010. 08.05.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2018. 09.25.




Diagnostics. Colonoscopy. Cleansing.
Na2SO4/K2SO4/MgSO4 Oral Tablets.
USA Approval Date: 2020. 11.10.
USA Launch Date: 2021. 01.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.27.




Diagnostics. Colonoscopy. Cleansing. PEG 3350+Na Ascorbate+Na2SO4+Ascorbic Acid+NaCl+KCl Powder for Oral Solution.
USA Approval Date: 2018. 05.07.
USA Launch Date : 2018. 09.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.




Diagnostics. Colonoscopy. Cleansing. Pulsed Irrigation Air+H2O Device.
Used during Procedure in case of Incom-
plete Pre-Procedure Cleaning.


EU Approval Date: 2021. 01.15. (2 Gen)
IL Approval Date: 2020. 04.07. (2 Gen)
USA Approval Date: 2019. 06.11. (2 Gen)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.18.




Diagnostics. Colonoscopy. Surgery. Polyp Removal.
EU Approval Date : 2016. 03.10.
USA Approval Date: 2017. 05.03.
(*) Company; Patents; TradeMark & Web-
Sites Available on Request.
UpDate: 2018. 09.25.




Diagnostics. Computed Tomography (CT) Colonography (Virtual Colonoscopy) >Computer Aided Detection (CAD) (I)
(*) Company; Patents & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.25.




Diagnostics. Computed Tomography (CT) Colonography (Virtual Colonoscopy) >Computer Aided Detection (CAD) (U)
Polyp Detection.
Launched in CA; EU & USA.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.




Diagnostics. Disposable Colonoscope. (D)
EU Approval Date : 2018. 03.20.
USA Approval Date: 2018. 01.09.
(*) Company : Ambu AS.
Web-Site : www.ambu.com
UpDate: 2018. 09.24.




Diagnostics. Disposable Colonoscope. (I)
Features>CMOS Camera
>Miniaturized
>No Sedation Required
>Self Navigating
>Self Propelling
Optical Colonoscopy Risk.
USA Clearance Date: 2014. 12.03.
USA Clearance Date: 2016. 09.20+
+Therapeutic Intervention.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.




Diagnostics. DNA Septin9 Blood Test.
AR Approval Date : 2014. 03.10.
CN Approval Date : 2014. 12.08.
EU Launch Date : 2011. 10.25.
USA Approval Date: 2016. 04.13.
USA Launch Date : 2016. 04.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.24.




Diagnostics. Experteam HNPCC Kit 1.
[METASTATIC; Mikro Satelliten Instabilitäts (MSI)]
(*) Company : Cytogen
Web-Site: www.cytogen.info/web/en/
UpDate: 2018. 09.28.




Diagnostics. Genomic Stool Test.
USA Approval Date: 2014. 08.12.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.




Diagnostics. Nucleosome Blood Test.
EU Approval Date: 2016. 12.28.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.25.




Dukes C (Stage III). Adjuvant. Brand.
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil.
USA Approval Date: 1998. 04.30.
(*) Company : Roche>Genentech.
Patent : Expired.
TradeMark: Xeloda.
UpDate: 2018. 09.27.




Dukes C (Stage III). Adjuvant. Generic.
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil.
USA Launch Date: 2019. 04.08.
(*) Company: Armas Pharmaceuticals.
UpDate: 2019. 11.14.




Individual. Treat. Matching Tissue Test.
Test Matches Individual Cancer Treat. From a Small Tissue Sample (Primary Tumor or Metastasis) Company generate Thousands of 3D Micro-Tumors (Tumoroids) that have the same properties as the Tumor/Metastasis in the Individual Patient. The Tumoroids are challenged with Single Drugs or Drug-Combinations. Immediately after finalization of the test, the patient will be put on the Test Guided Treatment. This is possible as the treatments tested are all approved by the health authorities.
EU Approval Date: 2018. 10.09.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.20.




Onco.>Prognostics>Colonoscopy>Narrow
Band Imaging.
Assess Neoplastic Potential of Polyps.
USA Clearance Date: 2021. 03.15.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.18.




Onco.>RadioTherapy>BrachyTherapy>Low Ra-
te Dose (LRD) BrachyTherapy.
>Indications Potential>
>atypical meningioma
>non-small-cell lung cancer
>ocular melanoma
>Indications Used>
>colorectal cancer
>gynecological cancer
>head and neck cancer
>pancreatic cancer
>soft tissue sarcomas
USA Approval Date: 2014. 08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




Paliative TREAT.: Levoleucovorin+ Combination CT with 5-FU. (METASTATIC)
USA Approval Date: 2011. 04.29.
(*) Company : Spectrum Pharma.
Patent : Expired
TradeMark: Fusilev
Web-Site : www.fusilev.com/
UpDate: 2018. 09.27.




Polyp Detector. AI Assisted Polyp Detec- tor.
EU CE Mark: 2019. 12.16.
(*) Company : Hoya Corp.>BUS.>Medical>
Pentax Medical
TradeMark: Discovery
Web-Site :
www.pentaxmedical.com/pentax/
UpDate: 2019. 12.27.




Polyp Removal. Flexible Microdebrider.
Flexible Shaver Technology.
Due to the lack of adequate resources, operators performing a colonoscopy typically only sample the largest polyps, exposing the patient to sample bias by typically leaving behind smaller less detectable polyps that could advance to colon cancer prior to future colonoscopy. Because of the sample bias, a negative result from the sampled polyps does not ensure the patient is truly cancer-free.
Clinical data shows that incomplete resection of colorectal disease is a challenge and rates of disease persistence are as high as 30 percent, leading to an increase in complications.
Unlike existing instruments, the Flexible Microdebrider performs tissue dissection, resection and retrieval in a single step enabling endoscopists to facilitate disease removal without thermal energy.
EU Approval Date : 2016. 03.10.
USA Approval Date: 2017. 05.03.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.28.




Prognostics. CTCs Detecting Test. (Metastatic).
Patent>Expiration Date: 2019. 02.12.
USA>Approval Date: 2006. 12.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.




Prognostics. Gene BioMarkers Blood Test.
CA>Ontario Launch Date: ?
USA Approval Date : 2012. 02.21.
USA Launch Date : 2012. 04.10.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.26.




Prognostics. Software. Approved in EU & IL
Description:
Software Analyzes EMRs. Particularly
"Total Blood Counts" for "Low Hemoglo
bin" trends
NO Patient Involvement
NO Blood Test
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.26.




Recurrence. Hyper Me BCAT1 & IKZF1 Genes PCR-Based Blood Test.
USA Launch Date: 2016. 12.20.
Blood ccfDNA Collection Tube>
>Collected in a Physicians Office.
>Implementation Date: 2017. 08.21.
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2019. 10.24.




Recurrence. Risk Immune Response Scoring In-Vitro Diagnostic Test.
(Early Stage/Localized Colon Cancer).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.10.




Recurrence. Stage II/III A/B Multi Gene Test.
WorldWide Avalaibility.
(*) Company : Genomic Health
TradeMark: OncoType DX.
Web-Site :
/www.genomichealth.com/en-US
UpDate: 2018. 09.26.




TREAT.: BevacizuMAb. Biosimilar. (META-STATIC)
Mechanism> VEGF Inhibition.
IN Launch Date: 2016. 06.27.
(*) Company : Hetero Drugs.
TradeMark: Cizumab
UpDate: 2018. 09.27.




TREAT.: BevacizuMAb. Biosimilar. (META-STATIC)
Mechanism> VEGF Inhibition.
USA Approval Date: 2017. 09.14.
USA Launch Date: 2019. 07.18.
(*) Company : Amgen.
TradeMark: Mvasi
UpDate: 2019. 11.12.




TREAT.: BevacizuMAb. Biosimilar. (META-STATIC)
Mechanism> VEGF Inhibition.
EU Approval Date : 2019. 02.19.
USA Approval Date: 2019. 06.28.
(*) Company : Pfizer.
TradeMark: ZIRABEV
UpDate: 2020. 01.08.




TREAT.: BevacizuMAb. Brand. (METASTATIC)
Mechanism> VEGF Inhibition.
USA Approval Date: 2004. 02.26.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.




TREAT.: Capecitabine Tab. Brand.
(METASTATIC)
>when Treat with Fluoropyrimidine>>Alone >is Preferred.
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil
USA Approval Date: 1998. 04.30
(*) Company : Roche>Genentech.
Patent : Expired
TradeMark: Xeloda
UpDate: 2018. 09.27.




TREAT.: Capecitabine Tab. Generic.
(METASTATIC)
>when Treat with Fluoropyrimidine>>Alone >is Preferred.
Nucleoside Metabolic Inhibitor.
ProDrug>Converts to 5-F Uracil
USA Launch Date: 2019. 04.08
(*) Company: Armas Pharmaceuticals.
UpDate: 2019. 11.14.




TREAT.: CetuxiMAb (METASTATIC; KRAS+).
>Companion Diagnostics>
Company : BioCept Inc.
Liquid Biopsy (Blood Test)
USA Launch Date: 2015. 08.05
USA Approval Date: 2009. 07.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.28.




TREAT.: Encorafenib+CetuxiMAb.
(METASTATIC>BRAFV600E+)
USA Approval Date: 2020. 04.08.
(Drug Combi.)
USA Launch Date: 2020. 04.15.
(Companion Diag.)
(*) Companies; TradeMarks & Web-Sites
Available on Request
UpDate: 2020. 04.16.




TREAT.: FluoroUracil Inj. Generics.
(AdenoCarcinoma)
(*) Company : Teva Pharmaceuticals USA.
TradeMark: Adrucil.
Web-Site : www.tevagenerics.com
UpDate: 2018. 09.27.




TREAT.: FOLFOX (ChemoTherapy)+Bevacizu Mab. (METASTATIC).
Artificial Intelligence-Powered Predic tor of FOLFOX response that utilizes
Company s tumor profiling results.
It is intended to be used as an aid in gauging a patient s likelihood to benefit from FOLFOX chemotherapy (in combination with bevacizumab) as the first-line chemotherapy regimen in metastatic colorectal adenocarcinoma.
FOLFOX: FOLinic acid (Leucovorin)
Fluorouracil (5-FU)
OXaliplatin (Eloxatin)
Launch Date: 2020. 03.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.01.




TREAT.: Fruquintinib Capsules. (METASTA-
TIC).
>Failed >2 Prior Systemic Therapies>
>including fluoropyrimidine, oxaliplatin
and irinotecan ..
CN Approval Date: 2018. 09.05.
CN Launch Date: 2018. 11.26.
(*) Companies: Eli Lilly.
Hutchison MediPharma
TradeMark: Elunate
UpDate: 2018. 11.27.




TREAT.: Irinotecan Inj.+5-Fluorouracil +Leucovorin. Brand. (METASTATIC)
Alkaloid>Camptothecin Deriv.
TopoIsomerase I Inhibition.
USA Initial Approval: 1996.
(*) Company : Pfizer.
Patent : Expired
TradeMark: CAMPTOSAR
UpDate: 2018. 09.27.




TREAT.: Irinotecan Inj.+5-Fluorouracil +Leucovorin. Generic. (METASTATIC)
Alkaloid>Camptothecin Deriv.
TopoIsomerase I Inhibition.
USA Launch Date: 2019. 05.07.
(*) Company : Armas Pharmaceuticals.
UpDate: 2019. 11.14.




TREAT.: LevoLeucovorin Inj.+Na+5-Fluoro-Uracil. (METASTATIC)
USA Approval Date: 2018. 10.23.
(*) Company; Patent & TradeMark Avai-
lable on Request.
UpDate: 2018. 10.24.




TREAT.: NivoluMAb [METASTATIC; Micro
Satellite Instability High (MSI-H)]
>Progressed Following Treat with>
Fluoropyrimidine, Oxaliplatin, &
Irinotecan
USA Approval Date: 2017. 08.01.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.16.




TREAT.: OxaliPlatin+ FluoroUracil +Leucovorin (FOLFOX). Brand. (METASTA-
TIC).
Stage III After Resection 1. Tumor.
USA Initial Approval Year: 2002.
(*) Company : Sanofi USA.
Patent : Expired.
TradeMark: Eloxatin.
UpDate: 2018. 09.27.




TREAT.: OxaliPlatin+ FluoroUracil +Leucovorin (FOLFOX). Generic. (METASTA-
TIC).
Stage III After Resection 1. Tumor.
(*) Company : Fresenius Kabi USA
UpDate: 2018. 09.27.




TREAT.: PanitumuMAb. (METASTATIC; KRAS+)
Companion K-RAS Diagnostics Test>
>Company : Qiagen
TradeMark : therascreen KRAS
>Company : BioCept Inc.
Liquid Biopsy (Blood Test)
USA Launch Date: 2015. 08.05.
>Company : Illumina
NGS Kit
TradeMark : MiSeqDx.
USA Approval Date: 2017. 06.29.
EU Approval Date: ?
USA 1st Approval: 2006. 09>
>monotherapy for the treatment of
patients with EGFR-expressing mCRC
after disease progression after prior
treatment with fluoropyrimidine-,
oxaliplatin-, and irinotecan-containing
chemotherapy.
USA 2nd Approval: 2014. 05>
>for use in combination with FOLFOX, as
first-line treatment in patients with
wild-type KRAS (exon 2) mCRC. With this
approval, PanitumuMAb became the first-
and-only biologic therapy indicated for
use with FOLFOX, one of the most
commonly used chemotherapy regimens, in
the first-line treatment of mCRC for
patients with wild-type KRAS mCRC.
USA 3rd Approval: 2017. 06>
>a refined indication for PanitumuMAb
for use in in patients with wild-type
RAS (defined as wild-type in both KRAS
and NRAS as determined by an FDA-
approved test for this use) mCRC.
(*) Company : Amgen
Patent : Expired 2017. 05.05.
TradeMark: Vectibix
Web-Site : www.vectibix.com
UpDate: 2018. 09.28.




TREAT.: PembrolizuMAb [METASTATIC; Mi-
cro Satellite Instability High (MSI-H)]
Mismatch Repair Deficient.
CA Approval Date: 2021. 03.08.
EU Approval Date: 2021. 01.26.
USA Approval Date: 2017. 05.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 03.09.




TREAT.: Regorafenib (METASTATIC)
Oral Multi-Kinase Inhibition.
CN, EU & JP Approval Date: ?
USA Approval Date: 2012. 09.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.




TREAT.: Trifluridine +Tipiracil Tablets. (METASTATIC)
EU Approval Date : 2016. 04.28.
JP Approval Date : ?
USA Approval Date: 2015. 09.22.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.27.




TREAT.: Ziv-Aflibercept Inj. for IV
Infusion. (METASTATIC).
USA Approval Date: 2012. 08.03.
(*) Company : Sanofi Genzyme
TradeMark: Zaltrap
Web-Site : www.zaltrap.com/
UpDate: 2018. 09.27.


>COLON CANCER. *'s products
This section has no products